Linda Garland

Linda Garland M.D.

Director, Clinicial Lung Cancer Program; Associate Professor of Clinical Medicine

Get in touch
    Specialty
  • Medical Oncology

About Dr. Garland

Accolades:

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Team Leader icon

    Team Leader

Linda Garland, M.D., knows all about the steep challenge that mesothelioma still presents to medical providers, but she also sees the future opportunities it brings.

Garland serves as director of the clinical lung cancer program and associate professor of clinical medicine at the University of Arizona Cancer Center. Hailing the recent advances in genetic tumor profiling, she contributed to an article entitled “Individualizing Mesothelioma Treatment: Small Steps into a Brighter Future.”

The article, co-authored by highly-regarded surgeon Raja Flores (Mount Sinai Medical Center, New York) and oncologist Anne Tsao (MD Anderson Cancer Center, Houston), calls for increasingly personalized treatments for mesothelioma patients based on those advances being made.

“[Mesothelioma’s] relative rarity, biologic heterogeneity and inherent chemotherapy- and radiation-resistance continue to challenge efforts to discover and develop novel therapeutic strategies,” she wrote. “However, the availability of pleural tumor from diagnostic pleural biopsies and pleurectomy specimens provides a distinct opportunity for molecular/genetic studies that can yield prognostic and predictive biomarkers, upon which individualized therapy can be designed.”

Talk to a Doctor About Your Diagnosis

We can help you or a loved one get in contact with Dr. Garland and find the treatment that's best for you.

Get Started Today

Research and Specialties

Garland, who specializes in medical oncology, has research interests in several malignant chest diseases and the use of experimental therapeutics. Diseases of particular interest to her include lung cancer, mesothelioma and other rare mediastinal tumors. She has a special interest in designing “finely-tuned” therapies.

Her clinical focus centers on mesothelioma, small-cell lung cancer, non-small cell lung cancer, head and neck cancer and thyroid cancer. While the prevalence of lung cancer has helped medical researchers make rapid advances in treatment, the rarity of mesothelioma (only 3,000 new cases annually in the United States) and previous lack of research money has produced slower growth. But the potential for dramatic, future progress exists.

We predict that over the next 5 to 10 years, we will have a small but expanding set of validated predictive and prognostic molecular/genetic biomarkers that can be used in the clinic to personalize the treatment of mesothelioma. Central to this framework is the rigorous harvesting and optimal processing of tumor and other relevant tissues for molecular/genetic analysis, now considered de rigueur for other tumor types such as NSCLC.”

– Linda Garland M.D.

She cites the personalization of chemotherapy as one strategy that may lead to improved clinical outcomes.

“There is new data suggesting that this will be possible for mesothelioma,” she explains. “Two studies have reported on predictive biomarker analysis for pemetrexed-based therapy.”

Personalized Medicine

Her quest for more personalized medicine isn’t limited to mesothelioma, which is caused by exposure to asbestos. She has done similar research with thyroid cancer, along with head and neck cancer and different types of lung cancer.

Quick Fact

In 2008, Dr. Garland was named as the principal investigator for a clinical trial of trimodal therapy as an intervention for mesothelioma patients and patients with other solid tumors.

“My clinical and research interests are in experimental therapeutics, with focus on malignant diseases of the chest,” she wrote as a summary of her research activity on the Arizona Cancer Center website. “Novel targets for therapeutic design, including targets in signal transduction pathways conferring drug resistance, are being identified. We are designing trials … thus providing more potent anti-cancer activity.”

Publications

In 2011, Garland authored “Chemotherapy for Malignant Mesothelioma,” which discussed the history and future of chemotherapeutics for mesothelioma patients. This article appeared in Current Treatment Options of Oncology, and her other articles have appeared in the Journal of Thoracic Oncology, Clinical Lung Cancer and the Journal of Clinical Oncology.

Disclaimer: Dr. Linda Garland has no professional affiliation with Asbestos.com.

Free VA Claims Assistance

Get Help Now

Qualify for Free Medical Care

See If You Qualify

Get Help Paying for Treatment

Learn More

Tim Povtak, Senior Content Writer at Asbestos.com

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Sources
  1. Garland, L., Flores, R. and Tsao. Clinical Lung Cancer. (2010). Individualized Mesothelioma Treatment: Small Steps Into a Brighter Future. Retrieved from http://cigjournals.metapress.com/content/92u1nv1360135767/fulltext.pdf
  2. University of Arizona Cancer Center. Linda L. Garland M.D. (2012). Retrieved from http://www.azcc.arizona.edu/profile/linda-garland
Get Help Contacting Linda Garland

View our resources for patients and families

Get Help Today
Get Your Free Mesothelioma Guide